LYRA · As filed with the SEC
Lyra Therapeutics balance sheet, by quarter
The statement as Lyra Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Balance Sheets · USD
| USD | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 | Q2 2024 Jun 30, 2024 | Q1 2024 Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | 15,893,000 | 22,055,000 | 29,784,000 | 31,735,000 | 40,577,000 | 23,800,000 | 31,905,000 | 15,799,000 |
| Short-term investments | — | — | — | — | 0 | 27,826,000 | 35,593,000 | 71,319,000 |
| Prepaid expenses and other current assets | 379,000 | 964,000 | 1,279,000 | 2,170,000 | 2,448,000 | 2,818,000 | 1,937,000 | 2,325,000 |
| Total current assets | 16,272,000 | 23,019,000 | 31,063,000 | 33,905,000 | 43,025,000 | 54,444,000 | 69,435,000 | 89,443,000 |
| Property and equipment, net | 1,051,000 | 1,122,000 | 1,159,000 | 1,276,000 | 1,404,000 | 1,613,000 | 1,665,000 | 3,783,000 |
| Operating lease right-of-use assets | 16,792,000 | 17,575,000 | 18,358,000 | 19,142,000 | 19,924,000 | 20,707,000 | 21,490,000 | 45,626,000 |
| Restricted cash | 1,993,000 | 1,993,000 | 1,993,000 | 1,993,000 | 1,993,000 | 1,992,000 | 1,992,000 | 1,992,000 |
| Other assets | — | — | — | — | 0 | — | — | 683,000 |
| Total assets | 36,108,000 | 43,709,000 | 52,573,000 | 56,316,000 | 66,346,000 | 78,756,000 | 94,582,000 | 141,527,000 |
| Current liabilities: | ||||||||
| Accounts payable | 663,000 | 627,000 | 680,000 | 725,000 | 1,179,000 | 2,292,000 | 4,971,000 | 2,844,000 |
| Restructuring liability | 3,266,000 | 3,059,000 | 3,486,000 | 4,039,000 | 4,347,000 | 4,855,000 | 3,127,000 | — |
| Accrued expenses and other current liabilities | — | 1,103,000 | 2,413,000 | 2,247,000 | — | 3,197,000 | 6,095,000 | 10,057,000 |
| Accrued expenses and other current liabilities | 775,000 | — | — | — | 2,586,000 | — | — | — |
| Operating lease liabilities | 4,818,000 | 4,684,000 | 4,552,000 | 4,243,000 | 4,121,000 | 4,003,000 | 4,269,000 | 4,504,000 |
| Deferred revenue | — | 7,000 | 32,000 | 216,000 | 398,000 | 607,000 | 814,000 | 1,319,000 |
| Total current liabilities | 9,522,000 | 9,480,000 | 11,163,000 | 11,470,000 | 12,631,000 | 14,954,000 | 19,276,000 | 18,724,000 |
| Operating lease liabilities, net of current portion | 25,441,000 | 26,695,000 | 27,926,000 | 29,113,000 | 30,259,000 | 31,321,000 | 32,479,000 | 33,356,000 |
| Deferred revenue, net of current portion | 11,862,000 | 11,862,000 | 11,862,000 | 11,861,000 | 11,862,000 | 11,862,000 | 11,850,000 | 11,943,000 |
| Total liabilities | 46,825,000 | 48,037,000 | 50,951,000 | 52,444,000 | 54,752,000 | 58,137,000 | 63,605,000 | 64,023,000 |
| Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2025 and 2024; 1,774,882 and 1,310,308 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 2,000 | 2,000 | 2,000 | 66,000 | 65,000 | 65,000 | 65,000 | 61,000 |
| Additional paid-in capital | 422,990,000 | 422,428,000 | 422,394,000 | 417,143,000 | 416,319,000 | 414,345,000 | 412,854,000 | 411,225,000 |
| Accumulated other comprehensive income, net of tax | — | — | — | — | 0 | 20,000 | (4,000) | 25,000 |
| Accumulated deficit | (433,709,000) | (426,758,000) | (420,774,000) | (413,337,000) | (404,790,000) | (393,811,000) | (381,938,000) | (333,807,000) |
| Total stockholders' (deficit) equity | (10,717,000) | (4,328,000) | 1,622,000 | 3,872,000 | 11,594,000 | 20,619,000 | 30,977,000 | 77,504,000 |
| Total liabilities and stockholders' (deficit) equity | 36,108,000 | 43,709,000 | 52,573,000 | 56,316,000 | 66,346,000 | 78,756,000 | 94,582,000 | 141,527,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.